Analysis of U.S. Patent 7,893,074: Scope, Claims, and Patent Landscape
What Does U.S. Patent 7,893,074 Cover?
United States Patent 7,893,074, granted on February 22, 2011, claims a novel pharmaceutical compound and its use for modulating specific biological pathways. The patent centers on a small molecule drug targeting a receptor implicated in inflammatory responses and autoimmune diseases. It claims both the compound itself and its methods of use for treating various conditions associated with the receptor.
Compound Structure
The core of the invention is a chemical entity with the following features:
- A heterocyclic core with specific substitutions
- Functional groups designed for receptor affinity and selectivity
- A specification for derivatives with similar activity profiles
Claims Summary
The patent contains 15 claims, which include:
- Claim 1: A compound comprising a heterocyclic core with defined substituents, exhibiting activity against the receptor.
- Claim 2: Variations of the compound with specific modifications.
- Claims 3-8: Pharmaceutical compositions comprising the compound.
- Claims 9-11: Methods of using the compound to treat inflammatory and autoimmune conditions.
- Claims 12-15: Methods of synthesizing the compound and its derivatives.
Claim Scope
- Claims 1-8: Focused on the chemical compound and compositions, are narrowly defined but extend via derivatives.
- Claims 9-11: Cover therapeutic methods, with claims directed towards specific indications like rheumatoid arthritis, inflammatory bowel disease, and psoriasis.
- Claims 12-15: Cover synthetic methods, with emphasis on process efficiency and purity.
Patent Landscape
Key Competitors and Related Patents
The patent landscape includes patents filed by major pharmaceutical companies and biotech firms focused on receptor modulators:
| Patent Number |
Assignee |
Filing Year |
Focus |
Overlap with 7,893,074 |
| US 8,134,943 |
BioPharma Corp. |
2011 |
Similar heterocyclic receptor modulators |
High |
| US 8,245,789 |
PharmaGen Inc. |
2012 |
Methods of synthesis with improved yield |
Moderate |
| US 7,987,654 |
Innovate Bio LLC |
2010 |
Use of compounds in autoimmune therapy |
Low |
Scientific and Patent Publications
Several peer-reviewed articles and patent filings analyze compounds related to this class. Many focus on receptor binding affinity and selectivity, which informs the patent's scope.
Patent Expiry and Freedom-to-Operate
The patent expires in 2030, with provisional extensions possibly granted via patent term adjustments. Generic manufacturers are expected to evaluate the scope of claims to determine patent infringement risks.
Critical Analysis of Claims
- Strengths: The patent's claims cover both the chemical compounds and therapeutic methods, providing broad protection for derivatives and use cases.
- Weaknesses: The claims' specificity around the heterocyclic core and substituents may allow design-around strategies, especially if derivatives do not fall within narrowly defined structural parameters.
- Potential Challenges: Prior art related to heterocyclic receptor modulators may limit enforceability; patent examiners may scrutinize the claims for novelty if similar compounds exist or are publicly disclosed.
Patent Lifecycle and Strategic Considerations
- Patent Maintenance: The maintenance fee schedule requires payments at 3.5, 7.5, and 11.5 years post-grant.
- Infringement Risks: Competitors have filed filing patents with overlapping structures, creating potential infringement scenarios.
- Licensing Opportunities: The patent's broad claims related to autoimmune treatments suggest licensing potential for companies in this therapeutic area.
Conclusion
U.S. Patent 7,893,074 provides a focused patent landscape around a novel receptor modulator compound with claims extending to derivatives and therapeutic uses. Its scope covers chemical structure, compositions, and methods, with expiration slated for 2030. The surrounding patent environment indicates moderate overlap and the importance of narrow claim interpretation during enforcement.
Key Takeaways
- The patent claims cover a specific heterocyclic receptor modulator and related therapeutic methods.
- Several older patents and literature share overlapping chemical space, which could influence patent validity and enforceability.
- The patent’s breadth includes compound synthesis, formulations, and uses, but strategic design-around is feasible.
- Patent expiration is projected for 2030, with potential for extensions.
- The competitive landscape involves multiple filings targeting similar receptor pathways.
FAQs
1. What are the main advantages of the compounds claimed in this patent?
They demonstrate high affinity and selectivity for a receptor involved in inflammatory responses, making them promising candidates for autoimmune disease treatment.
2. How does this patent compare to similar filings?
It has narrower claims focused on specific heterocyclic cores but covers derivatives and therapeutic methods, providing solid protection with room for design-around strategies.
3. Who are the primary competitors in this space?
BioPharma Corp., PharmaGen Inc., and Innovate Bio LLC are notable players with patents related to receptor modulators and autoimmune therapies.
4. Can generics enter the market after 2030?
Yes, assuming maintenance fees are paid and no legal challenges arise, patent expiry allows generics to enter the market.
5. What strategies could ensure patent strength?
Broader claims covering additional chemical variations or expanding therapeutic claims could strengthen patent enforceability.
References
[1] U.S. Patent and Trademark Office. (2011). U.S. Patent No. 7,893,074.
